• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Ruxolitinib improves symptoms in patients with disabling pansclerotic morphea

byDavid XiangandKiera Liblik
June 23, 2023
in Chronic Disease, Dermatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this case series, ruxolitinib was associated with improved inflammatory markers in patients with disabling pansclerotic morphea (DPM).

2. Ruxolitinib use was also associated with improved clinical symptoms in treated patients with DPM.

Evidence Rating Level: 1 (Excellent)

Study Rundown: DPM is a severe autoinflammatory disorder characterized by poor wound healing with rapidly progressive deep fibrosis. DPM is often refractory to systemic steroids, immunosuppression, and autologous stem-cell transplantation therapies. DPM is also associated with a substantially increased risk of squamous cell carcinoma. Ruxolitinib has been proposed to improve outcomes in patients with DPM with monoallelic gain-of-function variants in the gene encoding Signal Transducer and Activator of Transcription 4 (STAT 4). However, there is a gap in knowledge as to understanding the effect of ruxolitinib on DPM and whether it would appropriately inhibit the Janus Kinase (JAK)-STAT signaling pathway responsible for the manifestations of DPM. Overall, this study found that Ruxolitinib provided some benefit in improving the inflammatory markers and clinical symptoms in patients with gain-of-function variants in STAT4 caused by DPM. This study was limited by the small sample size of patients and patient families tested. Nevertheless, these study’s findings are significant, as they demonstrate that the JAK inhibitor ruxolitinib was associated with improvement in clinical symptoms and laboratory results in patients with STAT4 gain-of-function mutations caused by DPM.

Click to read the study in NEJM

Relevant Reading: Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease

RELATED REPORTS

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

Weighted vests and resistance training confer similar outcomes for bone density in the elderly

Food compounds associated with disease activity in inflammatory bowel disease 

In-Depth [case series]: This case series studied the disease course of four patients in three independent families with DPM. These patients had monoallelic gain-of-function variants in the gene encoding STAT4. Patients with this mutation were eligible for the study. The primary outcome measured was evaluated using patients’ blood samples. These samples were used to perform a host of laboratory tests such as flow cytometry, fluorescence imaging, wound-healing assays, and enzyme-linked immunosorbent assays. The clinical course of DPM in these patients was monitored, as well. Outcomes in the primary analysis were assessed via either the Student’s t-Test or the Kruskal-Wallis test. Based on the primary analysis, inhibition of Janus kinase (JAK)–STAT signaling with ruxolitinib led to an improvement in the hyperinflammatory fibroblast phenotype in vitro and resolution of inflammatory markers and clinical symptoms in treated patients, without adverse effects. Single-cell RNA sequencing revealed expression patterns consistent with an immunodysregulatory phenotype that was appropriately modified through JAK inhibition via ruxolitinib. In summary, this case series demonstrates that JAK inhibition via Rruxolitinib may provide improved dermatologic and inflammatory symptoms in patients with gain-of-function variants in STAT4 caused by DPM.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chronic diseasedermatologydisabling pansclerotic morpheageneticsimmunologypansclerotic morpheaRuxolitinibSTAT4
Previous Post

Withholding prophylactic platelet transfusion in thrombocytopenia increases adverse events

Next Post

No advantage of continuous vs intermittent meropenem in critically ill patients – the MERCY trial

RelatedReports

Chronic Disease

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

July 7, 2025
Chronic Disease

Weighted vests and resistance training confer similar outcomes for bone density in the elderly

June 27, 2025
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Food compounds associated with disease activity in inflammatory bowel disease 

June 25, 2025
Weekly Rewinds

2 Minute Medicine Rewind June 23, 2025

June 23, 2025
Next Post
Of Background Image

No advantage of continuous vs intermittent meropenem in critically ill patients – the MERCY trial

Gender conformity influences use of laxatives and muscle-building products

Mifepristone may be an effective therapeutic agent for adenomyosis-associated dysmenorrhea

Being overweight and obese associated with increased incidence of chronic kidney disease

2 Minute Medicine Rewind June 26, 2023

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cerebral embolic protection does not decrease stroke incidence in TAVI patients
  • Nerandomilast slows FVC decline in progressive pulmonary fibrosis
  • 2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.